
Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments 13 November 2023
Q3 2023 DANYELZA® net product revenues of $20.0 million represents YoY growth of 59% U.S. FDA clearance... Read more
Q3 2023 DANYELZA® net product revenues of $20.0 million represents YoY growth of 59% U.S. FDA clearance... Read more
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
NEW YORK, Oct. 18, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
Clearance of CD38-SADA IND marks the second clinical development program utilizing the Company’s novel... Read more
Naxitamab-based chemo-immunotherapy significantly improves long-term outcomes when administered early... Read more
Copenhagen, Denmark, 11 October 2023 – MinervaX ApS, a privately held Danish biotechnology company... Read more
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company”... Read more
Full enrolment and dosing commenced with its novel, prophylactic GBS vaccine in both healthy older adults... Read more
The Annual General Meeting in DANISH BIO-DANSK BIOTEK was held on 11 May 2023 at Børsen. The Minutes... Read more